
PMC:7784786 / 4307-11788
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
192 | 728-736 | Gene | denotes | IFN α-2b | Gene:3440 |
193 | 1036-1039 | Gene | denotes | ALP | Gene:470 |
194 | 1573-1577 | Gene | denotes | IL-6 | Gene:3569 |
195 | 1685-1689 | Gene | denotes | IL-6 | Gene:3569 |
196 | 1775-1779 | Gene | denotes | IL-1 | Gene:3553 |
197 | 1860-1887 | Gene | denotes | aspartate amino transferase | Gene:26503 |
198 | 1889-1892 | Gene | denotes | AST | Gene:26503 |
199 | 43-48 | Species | denotes | woman | Tax:9606 |
200 | 426-436 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
201 | 1275-1282 | Species | denotes | Patient | Tax:9606 |
202 | 1505-1512 | Species | denotes | patient | Tax:9606 |
203 | 535-541 | Chemical | denotes | oxygen | MESH:D010100 |
204 | 563-569 | Chemical | denotes | oxygen | MESH:D010100 |
205 | 571-574 | Chemical | denotes | PO2 | MESH:C093415 |
206 | 575-579 | Chemical | denotes | FiO2 | |
207 | 682-701 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
208 | 703-714 | Chemical | denotes | chloroquine | MESH:D002738 |
209 | 741-749 | Chemical | denotes | rocephin | MESH:D002443 |
210 | 1114-1124 | Chemical | denotes | itolizumab | MESH:C000597346 |
211 | 1170-1180 | Chemical | denotes | itolizumab | MESH:C000597346 |
212 | 1187-1190 | Chemical | denotes | PO2 | MESH:C093415 |
213 | 1191-1195 | Chemical | denotes | FiO2 | |
214 | 1607-1617 | Chemical | denotes | itolizumab | MESH:C000597346 |
215 | 2048-2058 | Chemical | denotes | itolizumab | MESH:C000597346 |
216 | 86-98 | Disease | denotes | hypertension | MESH:D006973 |
217 | 103-127 | Disease | denotes | Type 2 diabetes mellitus | MESH:D003924 |
218 | 155-163 | Disease | denotes | polypnea | |
219 | 230-239 | Disease | denotes | dry cough | MESH:D003371 |
220 | 282-290 | Disease | denotes | COVID-19 | MESH:C000657245 |
221 | 339-347 | Disease | denotes | COVID-19 | MESH:C000657245 |
222 | 472-481 | Disease | denotes | hypoxemia | MESH:D000860 |
223 | 486-507 | Disease | denotes | respiratory alkalosis | MESH:D000472 |
224 | 823-842 | Disease | denotes | respiratory failure | MESH:D012131 |
225 | 983-1016 | Disease | denotes | interstitial multifocal pneumonia | |
227 | 2134-2144 | Chemical | denotes | itolizumab | MESH:C000597346 |
234 | 2167-2177 | Chemical | denotes | itolizumab | MESH:C000597346 |
235 | 2313-2323 | Chemical | denotes | itolizumab | MESH:C000597346 |
236 | 2536-2546 | Chemical | denotes | itolizumab | MESH:C000597346 |
237 | 2663-2673 | Chemical | denotes | itolizumab | MESH:C000597346 |
238 | 2285-2301 | Disease | denotes | pleural effusion | MESH:D010996 |
239 | 2488-2504 | Disease | denotes | pleural effusion | MESH:D010996 |
241 | 2825-2832 | Species | denotes | patient | Tax:9606 |
246 | 2841-2845 | Gene | denotes | IL-6 | Gene:3569 |
247 | 2850-2853 | Gene | denotes | AST | Gene:26503 |
248 | 2912-2920 | Species | denotes | patients | Tax:9606 |
249 | 2928-2938 | Chemical | denotes | itolizumab | MESH:C000597346 |
303 | 4016-4019 | Gene | denotes | AST | Gene:26503 |
304 | 4047-4065 | Gene | denotes | C-reactive protein | Gene:1401 |
305 | 4188-4196 | Gene | denotes | IFN α-2b | Gene:3440 |
306 | 5152-5156 | Gene | denotes | IL-6 | Gene:3569 |
307 | 5267-5271 | Gene | denotes | IL-6 | Gene:3569 |
308 | 5424-5428 | Gene | denotes | IL-6 | Gene:3569 |
309 | 5472-5476 | Gene | denotes | IL-6 | Gene:3569 |
310 | 5478-5482 | Gene | denotes | IL-1 | Gene:3553 |
311 | 5563-5566 | Gene | denotes | AST | Gene:26503 |
312 | 3919-3926 | Species | denotes | Patient | Tax:9606 |
313 | 4590-4597 | Species | denotes | patient | Tax:9606 |
314 | 4864-4871 | Species | denotes | patient | Tax:9606 |
315 | 5065-5072 | Species | denotes | patient | Tax:9606 |
316 | 5718-5725 | Species | denotes | patient | Tax:9606 |
317 | 3611-3617 | Chemical | denotes | oxygen | MESH:D010100 |
318 | 4154-4173 | Chemical | denotes | lopinavir–ritonavir | MESH:C558899 |
319 | 4175-4186 | Chemical | denotes | chloroquine | MESH:D002738 |
320 | 4198-4207 | Chemical | denotes | meropenem | MESH:D000077731 |
321 | 4212-4221 | Chemical | denotes | linezolid | MESH:D000069349 |
322 | 4278-4288 | Chemical | denotes | itolizumab | MESH:C000597346 |
323 | 4420-4423 | Chemical | denotes | PO2 | MESH:C093415 |
324 | 4424-4428 | Chemical | denotes | FiO2 | |
325 | 4472-4475 | Chemical | denotes | PO2 | MESH:C093415 |
326 | 4476-4480 | Chemical | denotes | FiO2 | |
327 | 4506-4509 | Chemical | denotes | PO2 | MESH:C093415 |
328 | 5097-5107 | Chemical | denotes | itolizumab | MESH:C000597346 |
329 | 5186-5196 | Chemical | denotes | itolizumab | MESH:C000597346 |
330 | 5809-5823 | Chemical | denotes | norepinephrine | MESH:D009638 |
331 | 3015-3035 | Disease | denotes | ischemic cardiopathy | MESH:C536187 |
332 | 3047-3066 | Disease | denotes | atrial fibrillation | MESH:D001281 |
333 | 3068-3080 | Disease | denotes | hypertension | MESH:D006973 |
334 | 3085-3099 | Disease | denotes | hypothyroidism | MESH:D007037 |
335 | 3130-3140 | Disease | denotes | alcoholism | MESH:D000437 |
336 | 3219-3239 | Disease | denotes | respiratory diseases | MESH:D012140 |
337 | 3292-3311 | Disease | denotes | shortness of breath | MESH:D004417 |
338 | 3313-3318 | Disease | denotes | fever | MESH:D005334 |
339 | 3320-3328 | Disease | denotes | asthenia | MESH:D001247 |
340 | 3333-3342 | Disease | denotes | dry cough | MESH:D003371 |
341 | 3419-3427 | Disease | denotes | COVID-19 | MESH:C000657245 |
342 | 3479-3498 | Disease | denotes | respiratory failure | MESH:D012131 |
343 | 3516-3527 | Disease | denotes | tachycardia | MESH:D013610 |
344 | 3529-3537 | Disease | denotes | polypnea | |
345 | 3790-3809 | Disease | denotes | atrial fibrillation | MESH:D001281 |
346 | 3882-3891 | Disease | denotes | hypoxemia | MESH:D000860 |
347 | 3896-3917 | Disease | denotes | respiratory alkalosis | MESH:D000472 |
348 | 3936-3948 | Disease | denotes | leukocytosis | MESH:D007964 |
349 | 4663-4687 | Disease | denotes | alveolar hypoventilation | MESH:C536281 |
350 | 4717-4729 | Disease | denotes | pneumothorax | MESH:D011030 |
351 | 4764-4776 | Disease | denotes | pneumothorax | MESH:D011030 |
352 | 5738-5760 | Disease | denotes | myocardial dysfunction | MESH:D009202 |
353 | 5765-5770 | Disease | denotes | shock | MESH:D012769 |
354 | 5847-5851 | Disease | denotes | died | MESH:D003643 |
355 | 5875-5913 | Disease | denotes | cardiovascular and respiratory failure | MESH:D012131 |
381 | 6431-6439 | Gene | denotes | IFN α-2b | Gene:3440 |
382 | 7037-7041 | Gene | denotes | IL-6 | Gene:3569 |
383 | 7114-7118 | Gene | denotes | IL-6 | Gene:3569 |
384 | 7290-7294 | Gene | denotes | IL-1 | Gene:3553 |
385 | 7299-7304 | Gene | denotes | TNF-α | Gene:7124 |
386 | 7386-7389 | Gene | denotes | AST | Gene:26503 |
387 | 6099-6106 | Species | denotes | Patient | Tax:9606 |
388 | 6526-6533 | Species | denotes | Patient | Tax:9606 |
389 | 6961-6968 | Species | denotes | Patient | Tax:9606 |
390 | 7260-7267 | Species | denotes | patient | Tax:9606 |
391 | 6336-6342 | Chemical | denotes | Oxygen | MESH:D010100 |
392 | 6381-6392 | Chemical | denotes | ceftriaxone | MESH:D002443 |
393 | 6394-6413 | Chemical | denotes | lopinavir–ritonavir | MESH:C558899 |
394 | 6415-6426 | Chemical | denotes | chloroquine | MESH:D002738 |
395 | 6642-6652 | Chemical | denotes | itolizumab | MESH:C000597346 |
396 | 7222-7232 | Chemical | denotes | itolizumab | MESH:C000597346 |
397 | 5956-5964 | Disease | denotes | COVID-19 | MESH:C000657245 |
398 | 6133-6145 | Disease | denotes | hypertension | MESH:D006973 |
399 | 6147-6164 | Disease | denotes | diabetes mellitus | MESH:D003920 |
400 | 6166-6174 | Disease | denotes | glaucoma | MESH:D005901 |
401 | 6225-6230 | Disease | denotes | cough | MESH:D003371 |
402 | 6245-6253 | Disease | denotes | diarrhea | MESH:D003967 |
403 | 6272-6287 | Disease | denotes | viral pneumonia | |
404 | 6291-6299 | Disease | denotes | COVID-19 | MESH:C000657245 |
405 | 6829-6849 | Disease | denotes | respiratory distress | MESH:D012128 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T9 | 86-98 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T10 | 103-118 | Phenotype | denotes | Type 2 diabetes | http://purl.obolibrary.org/obo/HP_0005978 |
T11 | 155-163 | Phenotype | denotes | polypnea | http://purl.obolibrary.org/obo/HP_0002789 |
T12 | 230-239 | Phenotype | denotes | dry cough | http://purl.obolibrary.org/obo/HP_0031246 |
T13 | 472-481 | Phenotype | denotes | hypoxemia | http://purl.obolibrary.org/obo/HP_0012418 |
T14 | 486-507 | Phenotype | denotes | respiratory alkalosis | http://purl.obolibrary.org/obo/HP_0001950 |
T15 | 823-842 | Phenotype | denotes | respiratory failure | http://purl.obolibrary.org/obo/HP_0002878 |
T16 | 1007-1016 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T17 | 2285-2301 | Phenotype | denotes | pleural effusion | http://purl.obolibrary.org/obo/HP_0002202 |
T18 | 2488-2504 | Phenotype | denotes | pleural effusion | http://purl.obolibrary.org/obo/HP_0002202 |
T19 | 3037-3066 | Phenotype | denotes | permanent atrial fibrillation | http://purl.obolibrary.org/obo/HP_0004754 |
T20 | 3068-3080 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T21 | 3085-3099 | Phenotype | denotes | hypothyroidism | http://purl.obolibrary.org/obo/HP_0000821 |
T22 | 3130-3140 | Phenotype | denotes | alcoholism | http://purl.obolibrary.org/obo/HP_0030955 |
T23 | 3292-3311 | Phenotype | denotes | shortness of breath | http://purl.obolibrary.org/obo/HP_0002098 |
T24 | 3313-3318 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
T25 | 3320-3328 | Phenotype | denotes | asthenia | http://purl.obolibrary.org/obo/HP_0025406 |
T26 | 3333-3342 | Phenotype | denotes | dry cough | http://purl.obolibrary.org/obo/HP_0031246 |
T27 | 3479-3498 | Phenotype | denotes | respiratory failure | http://purl.obolibrary.org/obo/HP_0002878 |
T28 | 3516-3527 | Phenotype | denotes | tachycardia | http://purl.obolibrary.org/obo/HP_0001649 |
T29 | 3529-3537 | Phenotype | denotes | polypnea | http://purl.obolibrary.org/obo/HP_0002789 |
T30 | 3590-3609 | Phenotype | denotes | high blood pressure | http://purl.obolibrary.org/obo/HP_0000822 |
T31 | 3655-3665 | Phenotype | denotes | drowsiness | http://purl.obolibrary.org/obo/HP_0002329 |
T32 | 3790-3809 | Phenotype | denotes | atrial fibrillation | http://purl.obolibrary.org/obo/HP_0005110 |
T33 | 3882-3891 | Phenotype | denotes | hypoxemia | http://purl.obolibrary.org/obo/HP_0012418 |
T34 | 3896-3917 | Phenotype | denotes | respiratory alkalosis | http://purl.obolibrary.org/obo/HP_0001950 |
T35 | 3936-3948 | Phenotype | denotes | leukocytosis | http://purl.obolibrary.org/obo/HP_0001974 |
T36 | 4339-4360 | Phenotype | denotes | pulmonary infiltrates | http://purl.obolibrary.org/obo/HP_0002113 |
T37 | 4663-4687 | Phenotype | denotes | alveolar hypoventilation | http://purl.obolibrary.org/obo/HP_0002791 |
T38 | 4692-4703 | Phenotype | denotes | atelectasis | http://purl.obolibrary.org/obo/HP_0100750 |
T39 | 4717-4729 | Phenotype | denotes | pneumothorax | http://purl.obolibrary.org/obo/HP_0002107 |
T40 | 4764-4776 | Phenotype | denotes | pneumothorax | http://purl.obolibrary.org/obo/HP_0002107 |
T41 | 5765-5770 | Phenotype | denotes | shock | http://purl.obolibrary.org/obo/HP_0031273 |
T42 | 5894-5913 | Phenotype | denotes | respiratory failure | http://purl.obolibrary.org/obo/HP_0002878 |
T43 | 6133-6145 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T44 | 6147-6164 | Phenotype | denotes | diabetes mellitus | http://purl.obolibrary.org/obo/HP_0000819 |
T45 | 6166-6174 | Phenotype | denotes | glaucoma | http://purl.obolibrary.org/obo/HP_0000501 |
T46 | 6225-6230 | Phenotype | denotes | cough | http://purl.obolibrary.org/obo/HP_0012735 |
T47 | 6232-6240 | Phenotype | denotes | wheezing | http://purl.obolibrary.org/obo/HP_0030828 |
T48 | 6245-6253 | Phenotype | denotes | diarrhea | http://purl.obolibrary.org/obo/HP_0002014 |
T49 | 6278-6287 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T50 | 6829-6849 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T37 | 0-17 | Sentence | denotes | Cases description |
T38 | 18-28 | Sentence | denotes | Patient 1: |
T39 | 29-240 | Sentence | denotes | A 53-year old woman with a personal history of essential hypertension and Type 2 diabetes mellitus presented with symptoms of polypnea of more than 40 rpm, use of respiratory ancillary musculature and dry cough. |
T40 | 241-305 | Sentence | denotes | She arrived from a foreign country where COVID-19 was spreading. |
T41 | 306-437 | Sentence | denotes | Symptoms started on 23 March and COVID-19 was diagnosed on 26 March on the basis of positive real time PCR (RT-PCR) for SARS-CoV-2. |
T42 | 438-594 | Sentence | denotes | Initial gasometry showed moderate hypoxemia and respiratory alkalosis with a partial pressure of oxygen/fraction of inspired oxygen (PO2/FiO2) ratio of 191. |
T43 | 595-656 | Sentence | denotes | Chest x-rays showed interstitial lesions in both lung fields. |
T44 | 657-750 | Sentence | denotes | She started therapy with lopinavir/ritonavir, chloroquine, recombinant IFN α-2b and rocephin. |
T45 | 751-904 | Sentence | denotes | In spite of treatment, the illness subsequently progressed to hypoxemic respiratory failure warranting the initiation of invasive mechanical ventilation. |
T46 | 905-1089 | Sentence | denotes | At day 13 of her admission in the ICU, she showed radiologic worsening of the interstitial multifocal pneumonia, with elevation of ALP, LDH, erythrocyte sedimentation rate and D-dimer. |
T47 | 1090-1145 | Sentence | denotes | Physicians administered itolizumab at a dose of 200 mg. |
T48 | 1146-1274 | Sentence | denotes | After 48 h of the first itolizumab dose, PO2/FiO2 improved and there were evidences of radiological improvement (Figure 1A & B). |
T49 | 1275-1381 | Sentence | denotes | Patient was extubated after the first dose of the antibody and her status changed from critical to severe. |
T50 | 1382-1465 | Sentence | denotes | She received a second dose of the antibody (200 mg), 48 h after the first infusion. |
T51 | 1466-1572 | Sentence | denotes | 3 days after the first administration, patient was hemodynamically stable and has spontaneous ventilation. |
T52 | 1573-1684 | Sentence | denotes | IL-6 levels were evaluated before itolizumab administration and after 2 and 7 days of the first administration. |
T53 | 1685-1774 | Sentence | denotes | IL-6 levels reduced overtime from 172 pg/ml to 60 pg/ml (day 7) as depicted in Figure 2A. |
T54 | 1775-1846 | Sentence | denotes | IL-1 was evaluated at the same time intervals, but it was undetectable. |
T55 | 1847-2016 | Sentence | denotes | In addition, aspartate amino transferase (AST) concentrations were evaluated at different time points showing a reduction from 43 U/l to 24 U/l after 7 days (Figure 2B). |
T56 | 2017-2073 | Sentence | denotes | No adverse events related with itolizumab were reported. |
T57 | 2074-2083 | Sentence | denotes | Figure 1. |
T58 | 2085-2145 | Sentence | denotes | Radiological images before and after one dose of itolizumab. |
T59 | 2146-2273 | Sentence | denotes | Patient 1 (A) Before itolizumab (D0): diffuse Interstitial-alveolar infiltrate in both lung fields, predominantly in the bases. |
T60 | 2274-2477 | Sentence | denotes | Minor left pleural effusion. (B) After itolizumab (48 h): radiological improvement with decreased diffuse infiltrate and radio-opacity at the top of both lungs and in both lung bases, in less proportion. |
T61 | 2478-2514 | Sentence | denotes | The minor pleural effusion persists. |
T62 | 2515-2787 | Sentence | denotes | Patient 3 (C) Before itolizumab (D0): alveolar interstitial inflammatory infiltrate in both lung fields, predominantly on the right side. (D) After itolizumab (48 h): radiological improvement with significant decrease of the alveolar interstitial infiltrate of both lungs. |
T63 | 2788-2797 | Sentence | denotes | Figure 2. |
T64 | 2799-2840 | Sentence | denotes | Circulating biomarkers in patient's sera. |
T65 | 2841-2949 | Sentence | denotes | IL-6 and AST concentrations kinetics (A & B, respectively) measured in patients during itolizumab treatment. |
T66 | 2950-2960 | Sentence | denotes | Patient 2: |
T67 | 2961-3100 | Sentence | denotes | An 89-year old man with a personal history of chronic ischemic cardiopathy, permanent atrial fibrillation, hypertension and hypothyroidism. |
T68 | 3101-3240 | Sentence | denotes | He has a previous history of alcoholism and several hospital admissions in the last 3 months on account of infectious respiratory diseases. |
T69 | 3241-3343 | Sentence | denotes | He came to the hospital on 2 April after 7 days of shortness of breath, fever, asthenia and dry cough. |
T70 | 3344-3442 | Sentence | denotes | He was in contact with a person who returned from a foreign country, where COVID-19 was extending. |
T71 | 3443-3666 | Sentence | denotes | Physical examination shows signs of respiratory failure characterized by tachycardia, polypnea, intercostal and supraclavicular muscle retraction, high blood pressure, oxygen saturation of 82%, poor diuresis and drowsiness. |
T72 | 3667-3765 | Sentence | denotes | Chest x-rays showed bilateral pulmonary inflammatory infiltrates, predominantly in the right lung. |
T73 | 3766-3918 | Sentence | denotes | Admission ECG showed an atrial fibrillation with rapid ventricular response and the initial gasometry showed severe hypoxemia and respiratory alkalosis. |
T74 | 3919-4066 | Sentence | denotes | Patient also had leukocytosis, altered globular sedimentation rate as well as elevated values of AST, LDH, D-dimer and positive C-reactive protein. |
T75 | 4067-4138 | Sentence | denotes | He was admitted into the ICU requiring invasive mechanical ventilation. |
T76 | 4139-4236 | Sentence | denotes | Treatment with lopinavir–ritonavir, chloroquine, IFN α-2b, meropenem and linezolid was initiated. |
T77 | 4237-4436 | Sentence | denotes | 3 days after his admission into the ICU, itolizumab was prescribed, due to worsening of the bilateral pulmonary infiltrates together with a deterioration of the ventilatory function (PO2/FiO2 = 173). |
T78 | 4437-4575 | Sentence | denotes | After the first antibody infusion, PO2/FiO2 significantly increased (PO2/FiO2 = 320) and there were evidences of radiological improvement. |
T79 | 4576-4746 | Sentence | denotes | 3 days after, patient showed radiological worsening of the left lung, characterized by alveolar hypoventilation and atelectasis; then, a 70% pneumothorax was established. |
T80 | 4747-4859 | Sentence | denotes | Treatment of the pneumothorax with minimal pleurotomy was very demanding and required 3 days for the resolution. |
T81 | 4860-5054 | Sentence | denotes | The patient received a second infusion of the monoclonal antibody 72 h after the first, while a third dose was administered at the discretion of the treating physicians, 2 days after the second. |
T82 | 5055-5151 | Sentence | denotes | In total, patient received three doses of itolizumab (200 mg) without any related adverse event. |
T83 | 5152-5266 | Sentence | denotes | IL-6 levels were evaluated before itolizumab administration and after 2, 4 and 7 days of the first administration. |
T84 | 5267-5423 | Sentence | denotes | IL-6 was extremely high at baseline (623 pg/ml) and even though cytokine levels reduced roughly 50%, the lowest value remained above 300 pg/ml after 7 days. |
T85 | 5424-5460 | Sentence | denotes | IL-6 kinetics is shown in Figure 2A. |
T86 | 5461-5534 | Sentence | denotes | Apart from IL-6, IL-1 was undetectable at this time point of the disease. |
T87 | 5535-5628 | Sentence | denotes | Interesting, in the case of AST, a significant reduction is detecting at day 7 (pretreatment: |
T88 | 5629-5641 | Sentence | denotes | 156 U/l, D7: |
T89 | 5642-5676 | Sentence | denotes | 40 U/l) as is showed in Figure 2B. |
T90 | 5677-5824 | Sentence | denotes | After 10 days of admission into the ICU, patient presented a myocardial dysfunction and shock that required vasoactive support with norepinephrine. |
T91 | 5825-5914 | Sentence | denotes | On day 13, he finally died, on account of a mixed cardiovascular and respiratory failure. |
T92 | 5915-5925 | Sentence | denotes | Patient 3: |
T93 | 5926-6034 | Sentence | denotes | An 81-year old female, who is COVID-19 positive contact was not identified at the moment of hospitalization. |
T94 | 6035-6193 | Sentence | denotes | She started symptoms on 2 April and entered the ICU on 5 April. Patient has a previous history of hypertension, diabetes mellitus, glaucoma and smoking habit. |
T95 | 6194-6254 | Sentence | denotes | She was admitted with frequent cough, wheezing and diarrhea. |
T96 | 6255-6335 | Sentence | denotes | The diagnosis of viral pneumonia by COVID-19 was confirmed by RT-PCR on 7 April. |
T97 | 6336-6454 | Sentence | denotes | Oxygen support at 5 l/min and treatment with ceftriaxone, lopinavir–ritonavir, chloroquine and IFN α-2b was indicated. |
T98 | 6455-6525 | Sentence | denotes | Chest images showed bilateral interstitial infiltration in both lungs. |
T99 | 6526-6631 | Sentence | denotes | Patient condition was classified as severe, although she did not require invasive mechanical ventilation. |
T100 | 6632-6713 | Sentence | denotes | A dose of itolizumab (200 mg) was given the day after her admission into the ICU. |
T101 | 6714-6960 | Sentence | denotes | Two days after the antibody administration, together with the rest of the therapy, there was an improvement of the respiratory distress while the chest image showed a decrease of the alveolar interstitial infiltrate of both lungs (Figure 1C & D). |
T102 | 6961-7036 | Sentence | denotes | Patient left the ICU after a favorable clinical and radiological evolution. |
T103 | 7037-7113 | Sentence | denotes | IL-6 concentration was measured prior and after the antibody administration. |
T104 | 7114-7289 | Sentence | denotes | IL-6 level at baseline was lower than in previous cases (30 pg/ml), but also decreased 48 h and 168 h after itolizumab infusion, in parallel with patient recovery (Figure 2A). |
T105 | 7290-7372 | Sentence | denotes | IL-1 and TNF-α were untraceable before and 48 h after the antibody administration. |
T106 | 7373-7481 | Sentence | denotes | Regarding to AST concentration, the values were in the normal range during the treatment period (Figure 2B). |